“…As regards PK, it is important to study the absorption, distribution, metabolism, and excretion of candidate drugs in the liver, small intestine, and kidney [ 4 ]. In this context, hepatocytes and liver-derived materials are widely used in studies such as metabolite analysis (i.e., metabolomics) [ 5 , 6 ], inhibition or induction of cytochrome P450 (CYP) enzymes (at the mRNA, protein, and activity levels) [ 7 , 8 , 9 ], non-CYP enzyme metabolism [ 10 , 11 ], and prodrug metabolism [ 12 , 13 ]. On the other hand, hepatotoxicity (i.e., drug-induced liver injury, DILI) is often evaluated as part of an exploratory safety screening in the evaluation of new drug candidates.…”